Expert guidance on 510(k), De Novo, PMA submissions, and 21 CFR compliance. Written to help medical device companies navigate FDA regulatory pathways with confidence.
**Summary:** FDA classifies medical devices into three risk-based categories that determine the regulatory pathway (510(k), De Novo, or PMA) and oversight required. Correct classification is critical—wrong classification can delay market entry by 12–18 months or trigger enforcement action.
Manufacturers of 510(k)-cleared medical devices must determine whether modifications require a new submission or can be documented internally—getting this wrong risks regulatory action or unnecessary delays. FDA's 2017 guidance provides a decision framework based on whether changes "could affect" device safety or effectiveness, placing the burden on manufacturers to document their analysis regardless of outcome.
The 510(k) Executive Summary is a critical document that frames FDA reviewers' interpretation of your submission and directly impacts review timelines—a poorly organized summary triggers information requests that can delay clearance 90–180 days. This guide covers mandatory regulatory content, strategic framing, and common errors to distinguish summaries that accelerate clearance from those inviting scrutiny.